Tunicamycin enhances the apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand in endometriotic stromal cells

Hasegawa A, Akiko Hasegawa, A. Hasegawa, Yutaka Osuga, Osuga Y, Yasushi Hirota, Koji Hamasaki, Hamasaki K, Kahori Hamasaki, Ako Kodama, Kodama A, A. Kodama, Mutsuo Harada, Miyuki Harada, T. Tajima, Tajima T, Toshiki Tajima, Y. Takemura, Takemura Y, Yuri Takemura, Tetsuya Hirata, Osamu Yoshino, Yoshino O, Kaori Koga, Tetsu Yano, T Yano, Yano T, Yuji Taketani, Yojiro Taketani, Taketani Y
Human Reproduction · 2008 · vol. 24(2) , pp. 408–414 · doi:10.1093/humrep/den385 · PMID:18978361 · W2120585880
Lab / animal OA: bronze CC0 ⤵ 10 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Tunicamycin increased DR5 mRNA and TRAIL-induced apoptosis in endometriotic stromal cells, an effect inhibited by a caspase inhibitor and DR5 siRNA.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: The increase in concentration of osteoprotegerin, an antagonist of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), in the peritoneal fluid of women with endometriosis may interfere with TRAIL-induced apoptosis in endometriotic cells and promote the development of endometriosis. In the present study, the effect of tunicamycin, a possible apoptosis enhancer, on TRAIL-induced apoptosis in endometriotic stromal cells (ESC) was determined. METHODS: ESC were isolated from cyst walls of ovarian endometrioma and cultured. ESC were incubated with or without tunicamycin (2 microg/ml) for the first 16 h, and then incubated with or without TRAIL (200 ng/ml) for the following 24 h. To examine whether caspases were involved in TRAIL-induced apoptosis, z-VAD-fmk (30 microM), a general caspase inhibitor, was added 1 h before TRAIL treatment. ESC were transfected with small interfering RNA (siRNA) for DR5, a receptor of TRAIL, before tunicamycin treatment to evaluate its role in ESC. DR5 mRNA level was determined by quantitative RT-PCR. Apoptosis in ESC was evaluated by flow cytometry. RESULTS: Tunicamycin increases both DR5 mRNA (P < 0.005) and TRAIL-induced apoptosis (P < 0.0001) in ESC. The increase in TRAIL-induced apoptosis in ESC by tunicamycin was suppressed (P < 0.05) by z-VAD-fmk. Transfection with DR5 siRNA suppressed the tunicamycin-induced increase in DR5 mRNA and abrogated the up-regulation of TRAIL-induced apoptosis by tunicamycin. CONCLUSIONS: The combined treatment with tunicamycin and TRAIL may have therapeutic potential in the treatment of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Anti-Bacterial Agents Apoptosis Endometriosis Stromal Cells TNF-Related Apoptosis-Inducing Ligand Tunicamycin Anti-Bacterial Agents Anti-Bacterial Agents Apoptosis Apoptosis Cells, Cultured Cells, Cultured Endometriosis Endometriosis Female Female Gene Expression Gene Expression Gene Expression Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (26)

Cited by (11)

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:05:57.285809+00:00
License: CC0 · commercial use OK